<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The effect of microbiologic and clinical factors on procalcitonin levels*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The effect of microbiologic and clinical factors on procalcitonin levels*</h1>
<div class="graphic"><div class="figure"><div class="ttl">The effect of microbiologic and clinical factors on procalcitonin levels*</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1"> </td> <td class="subtitle1">Rise &gt;0.25 ng/mL</td> <td class="subtitle1">No rise or rise &lt;0.25 ng/mL</td> </tr> <tr> <td colspan="3"><strong>Infections</strong><sup>¶</sup></td> </tr> <tr> <td class="indent1" colspan="3">Bacterial</td> </tr> <tr> <td class="indent2">Typical respiratory bacteria</td> <td> <ul> <li>Most reported thus far</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent2">Atypical respiratory bacteria</td> <td> <ul> <li><em>Legionella</em> spp</li> </ul> </td> <td> <ul> <li><em>Chlamydia pneumoniae</em></li> <li><em>Mycoplasma pneumoniae</em></li> </ul> </td> </tr> <tr> <td class="indent2">Mycobacteria</td> <td> <ul> <li>Mycobacteria spp<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>Mycobacteria spp<sup>Δ</sup></li> </ul> </td> </tr> <tr> <td class="indent2">Other bacteria</td> <td> <ul> <li><em>Orientia tsutsugamushi</em> (scrub typhus)</li> </ul> </td> <td> <ul> <li>European <em>Borrelia</em> spp (Lyme borreliosis)</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3">Viral</td> </tr> <tr> <td> </td> <td> <ul> <li>None reported thus far</li> </ul> </td> <td> <ul> <li>All reported thus far</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3">Fungal</td> </tr> <tr> <td> </td> <td> <ul> <li><em>Candida</em> spp</li> </ul> </td> <td> <ul> <li>Aspergillosis</li> <li>Coccidioidomycosis</li> <li>Mucormycosis</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3">Parasitic</td> </tr> <tr class="divider_bottom"> <td> </td> <td> <ul> <li><em>Plasmodium</em> spp (malaria)</li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong>Toxin-mediated illnesses</strong></td> <td> <ul> <li>Severe <em>Clostridioides</em> <em>difficile</em>-associated disease<sup>◊</sup></li> <li>Mushroom poisoning</li> </ul> </td> <td> <ul> <li><em>C. difficile</em> colonization</li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Severe physiologic stress</strong></td> <td> <ul> <li>Burns</li> <li>Trauma</li> <li>Surgery</li> <li>Bowel ischemia</li> <li>Pancreatitis</li> <li>Intracerebral hemorrhage</li> <li>Ischemic stroke</li> <li>Shock of any kind (septic, anaphylactic, hemorrhagic, or cardiogenic)</li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong>Immune disorders and rheumatologic conditions</strong></td> <td> <ul> <li>Kawasaki disease</li> </ul> </td> <td> <ul> <li>Gout and pseudogout</li> <li>Inflammatory bowel disease</li> <li>Systemic lupus erythematosus</li> <li>Rheumatoid arthritis</li> <li>Granulomatosis with polyangiitis</li> <li>Still's disease</li> <li>Temporal arteritis</li> <li>Behçet syndrome</li> <li>Polyarteritis nodosa</li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Malignancies</strong></td> <td> <ul> <li>Medullary thyroid cancer</li> <li>Lung cancers with neuroendocrine components</li> </ul> </td> <td> <ul> <li>Lymphoma</li> <li>Sarcoma</li> <li>Pancreatic cancer</li> <li>Renal cell carcinoma</li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Other comorbidities</strong></td> <td> <ul> <li>Renal insufficiency</li> <li>Severe liver disease</li> </ul> </td> <td> </td> </tr> <tr> <td><strong>Drugs</strong></td> <td> <ul> <li>Alemtuzumab (CD52 antibody)</li> <li>Granulocyte transfusions</li> <li>Interleukin 2</li> <li>Rituximab (anti-CD20 antibody)</li> <li>T-cell antibodies</li> </ul> </td> <td> <ul> <li>Glucocorticoids</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>* Conditions listed in this table are derived from case series and reports in the medical literature.</p>
<p>¶ Contained infections such as abscesses or empyema may not cause procalcitonin to rise.</p>
<p>Δ Both rise and lack of rise of procalcitonin have been reported with mycobacterial infections.</p>
◊ Effect of <em>C. difficile</em> infection on procalcitonin levels not fully defined.</div><div class="graphic_reference">Data from:
<ol>
<li>Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 Suppl 4:S346.</li>
<li>Scheinpflug K, Schalk E, Grabert E, Achenbach HJ. Procalcitonin is not useful to discriminate between infectious and noninfectious CRP elevation in patients with non-small cell lung cancer. Infect Control Hosp Epidemiol 2015; 36:1117.</li>
<li>Rao K, Walk ST, Micic D, et al. Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One 2013; 8:e58265.</li>
<li>Li G, Zhu C, Li J, et al. Increased level of procalcitonin is associated with total MRI burden of cerebral small vessel disease in patients with ischemic stroke. Neurosci Lett 2018; 662:242.</li>
<li>He D, Zhang Y, Zhang B, et al. Serum procalcitonin levels are associated with clinical outcome in intracerebral hemorrhage. Cell Mol Neurobiol 2017.</li>
<li>Reinink AR, Limsrivilai J, Reutemann BA, et al. Differentiating Clostridium difficile colitis from Clostridium difficile colonization in ulcerative colitis: A role for procalcitonin. Digestion 2017; 96:207.</li>
<li>Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis 2014; 59:1761.</li>
</ol></div><div id="graphicVersion">Graphic 117053 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
